Eisai: “LEQEMBI” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
TOKYO and CAMBRIDGE, Mass., June 28, 2024 – (JCN Newswire) – Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab) has been launched in China. LEQEMBI received approval in January 2024 as a treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD dementia…
Read More
0
